Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2026)
Entrada Therapeutics (TRDA) reported EBITDA Margin of -4917.93% for Q2 2026, down 2571.83 percentage points from -2346.10% a year earlier and down 175.30 percentage points from the prior quarter.
Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Entrada Therapeutics' EBITDA Margin came in at -3688.22%, down 3572.19 percentage points year-over-year; for FY2025, it was -605.00%, down 629.11 percentage points from FY2024.
- By year, EBITDA Margin came in at 24.11% in FY2024 (+24.35 pp) and -0.25% in FY2023.
- The Q2 2026 figure ranks as the lowest quarterly EBITDA Margin in data going back to Q1 2023.
- Year over year, EBITDA Margin has now declined in each of the last eight quarters, with an average year-over-year change of -1978.02 percentage points over the last eight quarters.
- The high point for year-over-year EBITDA Margin in five years was Q2 2024 (a gain of 143.22 percentage points); the low point was Q1 2026 (a drop of 4641.24 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at -4742.63% (Q1 2026), -3180.75% (Q4 2025) and -2840.83% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 39.10% |
| 10 | Entrada Therapeutics | 243.74 Mn | 243.74 Mn | - | -4,917.93% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4,917.93% |
| Mar 31, 2026 | -4,742.63% |
| Dec 31, 2025 | -3,180.75% |
| Sep 30, 2025 | -2,840.83% |
| Jun 30, 2025 | -2,346.10% |
| Mar 31, 2025 | -101.39% |
| Dec 31, 2024 | -13.01% |
| Sep 30, 2024 | -106.07% |
| Jun 30, 2024 | 57.37% |
| Mar 31, 2024 | 37.29% |
| Dec 31, 2023 | 13.48% |
| Sep 30, 2023 | 33.87% |
| Jun 30, 2023 | -85.85% |
| Mar 31, 2023 | -20.74% |
Entrada Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TRDA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "TRDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TRDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();